Often when a patient walks into a provider's office, he or she might not have any idea about the total cost of the visit-except what the copay might be.
Often when a patient walks into a provider's office, he or she might not have any idea about the total cost of the visit-except what the copay might be.
"In today's world there is a lot of confusion related to consumers understanding their obligation, in that they do not pay for their out-of-pocket costs in a consistent, timely or an efficient manner," says Bill Fandrich, HealthePass Product Executive, for Bloomfield, Conn.-based CIGNA Healthcare. He projects that patients' payments to providers will more than double in the next five years. "The healthcare payment process still operates under the traditional managed-care model, which is a copay patient obligation model that does not effectively address deductible and co-insurance payment obligation," he adds.
To fulfill that need, CIGNA plans to launch its HealthePass solution in 2007 with some of the largest hospital systems and physician groups in the United States. At its core, HealthePass consists of a robust, comprehensive cost calculator that will supply accurate, personalized estimates of patient liability and is intended to be an easily adopted tool for providers that will clearly set financial expectations, shorten providers' revenue cycles and significantly reduce the potential for patient bad debt.
PROVIDER PERSPECTIVE
HealthePass is the product of a thorough reassessment of the healthcare marketplace by CIGNA. While many in the industry might have explored real-time claims adjudication and debit cards, CIGNA also sought input from providers, physician groups, hospitals, employers and others to see the industry from a provider's perspective, according to Fandrich.
"We took a step back and did several months of detailed market analysis, including hundreds of hours of interviews with providers," Fandrich says. "As a byproduct of that, we saw the need to introduce a different kind of solution, one that could work across the various provider business models. We needed to provide a solution that could cross products-PPO plans, consumer-directed plans and other plans with a wide variety of benefit options. We needed to provide a very simple way for both the consumer and provider to understand the patient's financial obligation."
Significant among its multiple functions, HealthePass ensures there is a shared understanding of the patient obligation during the healthcare delivery cycle-before, during or after treatment. Whereas most cost calculators today use the "charge" information to make non-specific cost estimates, HealthePass's calculator generates an estimate based on the specific treatment, provider contract, and a real-time snapshot of the patient's covered benefits.
ICER Identifies 5 Drugs with Unsupported Price Increases
December 12th 2024The Institute for Clinical and Economic Review has identified five drugs — Biktarvy, Darzalex, Entresto, Cabometyx, and Xeljanz — with prices increases that are not supported by new clinical evidence, with a total of $815 million in added costs to U.S. payers in 2023.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Study Highlights Critical Need For Improved Understanding of Childhood Interstitial Lung Disease
December 10th 2024Diagnostic criteria for pulmonary fibrosis and other fibrotic diseases in children are lacking. That void hampers an understanding of how disease progresses in children and adolescents and what the outcomes are.
Read More